Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Mazen S. Zenati"'
Autor:
Nathan Bahary, Alessandro Paniccia, Samer AlMasri, Kenneth K. Lee, Mazen S. Zenati, Pranav Murthy, Annissa Desilva, Michael T. Lotze, Aatur D. Singhi, Richard L. Simmons, Amer H. Zureikat
Publikováno v:
Journal of Clinical Oncology. 39:4126-4126
4126 Background: Pancreatic ductal adenocarcinoma (PDAC) is an aggressive disease characterized by chronic inflammation and a tolerogenic immune response. Neutropenia is a common side effect of cytotoxic chemotherapy, managed with administration of r
Autor:
Nathan Bahary, Herbert J. Zeh, Mashaal Dhir, Amer H. Zureikat, Aatur D. Singhi, Mazen S. Zenati, Melissa E. Hogg, Ahmad Hamad
Publikováno v:
Journal of Clinical Oncology. 36:402-402
402 Background: Comparative effectiveness of FOLFIRINOX and Gemcitabine/nab-paclitaxel (G-nP) in the neoadjuvant treatment (NAT) of pancreatic ductal adenocarcinoma (PDA), remains unknown. The aim of this study was to perform a propensity matched ana
Autor:
Amer H. Zureikat, Melissa E. Hogg, Jennifer Steve, Filip Bednar, Sharon Winters, Lee M. Ocuin, Mazen S. Zenati, Nathan Bahary, Herbert J. Zeh
Publikováno v:
Journal of Clinical Oncology. 34:399-399
399 Background: Locally advanced (LA) unresectable pancreatic adenocarcinoma (PDA) historically portends a poor prognosis with a median OS of 9-11 months. Recently, two multi-drug regimens – FOLFIRINOX and gemcitabine/nab-paclitaxel – have proven
Autor:
David L. Bartlett, Amer H. Zureikat, Mazen S. Zenati, Melissa E. Hogg, Jennifer Miller, Jennifer Steve, Herbert J. Zeh, Nathan Bahary, Lee M. Ocuin, Aatur D. Singhi, Steven A. Burton
Publikováno v:
Journal of Clinical Oncology. 34:311-311
311 Background: The role of RT following PD for PDA remains controversial due to ambiguity in the definition of R0/R1 margin status in existing clinical trials. Recent data suggest that increased margin clearance (MC) is associated with improved surv